4
views
0
recommends
+1 Recommend
2 collections
    0
    shares

      Call for Papers: Digital Diagnostic Techniques

      Submit here before August 31, 2024

      About Pathobiology5.0 Impact Factor I 7.7 CiteScore I 1.088 Scimago Journal & Country Rank (SJR)

      • Record: found
      • Abstract: found
      • Article: found

      Study on the Efficacy of Sacubitril/Valsartan in Patients with Heart Failure with Preserved Ejection Fraction Undergoing Peritoneal Dialysis

      research-article

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Introduction: Cardiovascular disease is the most common cause of death and morbidity in patients with end-stage renal disease. Sacubitril/valsartan (SAC/VAL) can reduce the risk of cardiovascular mortality among patients with heart failure (HF). The present study set out to evaluate the efficacy of SAC/VAL in the treatment of patients with HF with preserved ejection fraction (HFpEF) undergoing peritoneal dialysis (PD) (HFpEF&PD). Methods: A total of 160 patients with HFpEF&PD were enrolled and randomly divided into the control group ( N = 80) and SAC/VAL group ( N = 80). The cardiac function efficacy, HF scoring efficacy, echocardiographic parameters, serological indicators, and 6-minute walking test were compared before and after treatment. Results: After 6 months of treatment, the total number of patients who responded to treatment in the SAC/VAL group was higher than that of the control group in terms of cardiac function and HF scoring efficacy. After treatment, levels of early diastolic/late diastolic filling velocity and left ventricular ejection fraction were increased in both groups, while the levels of left atrial diameter, left ventricular end-diastolic diameter, left ventricular end-systolic diameter, inter-ventricular septal diameter, and left ventricular posterior wall diameter were decreased; the NT-proBNP levels were diminished in both groups, while hemoglobin levels and the 6-minute walk distance were increased; the systolic blood pressure, diastolic blood pressure, and 24-h ultrafiltration volume were lowered in all patients. The changes in these indexes in the SAC/VAL group were more obvious than those in the controls. Conclusion: SAC/VAL can significantly improve cardiac function in patients with HFpEF&PD.

          Related collections

          Author and article information

          Journal
          CRD
          Cardiology
          10.1159/issn.0008-6312
          Cardiology
          Cardiology
          S. Karger AG
          0008-6312
          1421-9751
          2023
          October 2023
          30 May 2023
          : 148
          : 5
          : 385-394
          Affiliations
          Department of Nephrology, Cangzhou Central Hospital, Cangzhou, China
          Article
          531217 Cardiology 2023;148:385–394
          10.1159/000531217
          37253340
          6c5edd81-2831-44fa-84f0-e5ead4035de8
          © 2023 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.

          History
          : 06 December 2022
          : 22 May 2023
          Page count
          Figures: 3, Tables: 5, Pages: 10
          Funding
          This work was supported by Cangzhou Key Research and Development Program Guidance Project (No. 213106075).
          Categories
          HF and Intensive Care: Research Article

          Medicine
          Peritoneal dialysis,Heart failure with preserved ejection fraction,Sacubitril/valsartan,Cardiac function,N-Terminal pro-brain natriuretic peptide,Volumetric loading,24‐h ultrafiltration volume,Efficacy

          Comments

          Comment on this article